Key points are not available for this paper at this time.
Secondary hyperparathyroidism is a major metabolic complication in patients under chronic hemodialysis (CHD) treatment. Parathyroidectomy (PTx) remains a valid treatment option, especially when PTH-lowering therapies fail to respond to medical or pharmacological therapy, as advocated in the 2017 CKD-MBD Guideline update in patients with CKD G3a–G5D (2B, moderate level of evidence). The objective is to describe the results and complications of 61 PTx performed in 52/519 patients (under CHD through years 1996-2022.
Cusumano et al. (Mon,) studied this question.